Free Newsletter
Pharma layoffs plummet to 255 in August
After seeing pharma job cut numbers dwell in the thousands for several month, consulting firm Challenger, Gray and Christmas report that pharma layoffs plunged to just 255 in August. That's the lowest total of any month this year, replacing March as the month with the fewest job cuts. The total number of positions eliminated climbed to 37,265.
Pharma Layoffs by Month, 2010
| Month | Layoffs |
| January | 8,170 |
| February | 25,875 |
| March | 308 |
| April | 1,049 |
| May | 6,943 |
| June | 830 |
| July | 2,023 |
| August | 255 |
| TOTAL | 37,265 |
Source: Challenger, Gray & Christmas
August job cuts were down 17 percent from the 41,676 cuts announced in July, according to the report. Last month not only replaces April as the lowest job-cut month of the year, it represents the lowest job-cut month since June 2000, when employers announced only 17,241 planned layoffs.
August was the first month Pharma made Challenger's list of industry that revealed hiring plans, but don't get too excited yet: pharma companies announced plans to hire just eight employees. The industry still ranks second overall for the most jobs cut in 2010.
Top Five Industries, Year to Date
| Industry | 2010 | 2009 |
| Government/Non-Profit |
112,378 |
109,433 |
| Pharmaceutical | 37,265 |
52,683 |
| Retail |
30,805 |
88,352 |
| Computer |
20,102 |
61,578 |
| Telecommunications |
18,903 |
53,145 |
- here's the Challenger release
Related Articles:
Pharma cuts 2,023 jobs in July
Pharma layoffs near 35K in first half of 2010
Report: Pharma cuts 6,943 jobs in May
Pharma layoffs plunge to just 308 in March
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: